Pattern Bioscience, Inc., an innovator in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, has announced the completion of a US$28.7 million Series C financing. The latest funding round was led by Illumina Ventures and Omnimed Capital and includes participation from the Antimicrobial Resistance Action Fund and Daleshaw Ltd. This new round brings the company’s total funding raised to date to US$68 million.

Latham & Watkins LLP represents Pattern Bioscience in the deal with an emerging companies team led by Austin partner Scott Craig with Houston associate Cecilia Turchetti.